SB 133 would prohibit the use of “co-pay accumulator” practices for prescription drugs in several types of health coverage in Indiana. Under the bill, when a covered person or someone paying on that person’s behalf pays for a prescription drug, that amount must count toward the person’s out-of-pocket maximum or other cost-sharing requirement. The bill applies to state employee health plans, pharmacy benefit managers, insurers issuing accident and sickness policies, and health maintenance organizations, for plans or contracts entered into, renewed, amended, or delivered after June 30, 2025.
The bill also limits the rule’s application when a brand-name drug has a generic alternative available. In those cases, the accumulator protection does not apply unless the covered person obtained the brand-name drug through prior authorization, step therapy, or an exceptions/appeals process. The bill defines “generic alternative” as an FDA-designated therapeutically equivalent drug that is nationally available.
Impact
SB 133 would amend multiple sections of the Indiana Code governing state employee health plans and private health insurance to require prescription drug payments made by or on behalf of a covered person to count toward deductibles, out-of-pocket maximums, and similar cost-sharing limits. This would affect state employee coverage, pharmacy benefit managers, insurers, and HMOs, and would likely reduce the amount of cost sharing that remains after a manufacturer coupon or other third-party payment is used. The bill is effective July 1, 2025, and applies prospectively to new, renewed, amended, or delivered plans and policies after June 30, 2025.
Sentiment
The bill’s framing and caption suggest a consumer-protection approach aimed at helping patients receive full credit for prescription drug spending. In the materials provided, there is no recorded committee testimony or vote history, so there is no documented public debate to indicate support or opposition. Based on the text alone, the bill appears designed to be favorable to insured patients who rely on prescription assistance or third-party payments.
Contention
The main policy tension in SB 133 is between patient affordability and insurer/pharmacy benefit manager cost-management tools. Supporters would likely emphasize that accumulator programs can prevent patients from benefiting from manufacturer assistance and can delay reaching cost-sharing limits. Potential opponents may argue that the bill could increase plan costs and reduce the ability of insurers and PBMs to steer patients toward lower-cost generic alternatives. The bill addresses part of that concern by excluding cases where a generic alternative exists unless the brand-name drug was obtained through prior authorization, step therapy, or an appeals process.